Latest Headlines
-
Convergent Therapeutics Announces FDA Clearance Of IND Application For CONV01-α, A Best-In-Class Radioantibody Targeting Prostate-Specific Membrane Antigen
4/2/2024
Convergent Therapeutics Inc., a clinical stage biotechnology company focused on developing next generation radiopharmaceutical therapies for the treatment of prostate cancer and other cancers, today announced that the U.S. Food and Drug Administration ("FDA") has cleared the investigational new drug ("IND") application for CONV01-α, its lead candidate for the treatment of patients with advanced prostate cancer.
-
Infinant Health Announces Submission Of Orphan Drug Designation Application
4/2/2024
Infinant Health, a privately-held company focused on changing the trajectory of human health, one baby at a time, announced it has filed an application with the U.S. Food and Drug Administration (FDA) to receive Orphan Drug Designation (ODD) for its drug candidate INF108 for the prevention of necrotizing enterocolitis in pre-term infants.
-
Mosaic Biosciences Expands Its Leading Drug Discovery And Development Expertise
4/2/2024
Mosaic Biosciences, a drug discovery organization that provides comprehensive protein and antibody therapeutics research expertise to its biotech, biopharma, and academic partners, today announced two strategic leadership additions to its team: Malavi Madireddi, PhD, as Senior Vice President, Drug Discovery, and Scott Glaser, PhD, as Senior Vice President, Biologics Discovery. Both recognized leaders join the company as it grows to meet increased demand for its comprehensive and integrated drug discovery research services.
-
New Antibiotic Class Effective Against Multidrug-Resistant Bacteria
4/1/2024
Scientists at Uppsala University have discovered a new class of antibiotics with potent activity against multi-drug resistant bacteria, and have shown that it cures bloodstream infections in mice. The new antibiotic class is described in an article in the scientific journal PNAS.
-
New Synthesis Platform Allows For Rapid Cancer Drug Synthesis And Testing
4/1/2024
The discovery of new compounds with pharmacological properties can be expensive and time-consuming. Therefore, there is an increasing interest in developing workflows that allow for the rapid synthesis and testing of multiple compounds in parallel.
-
Otsuka And Click Therapeutics Announce The U.S. Food And Drug Administration (FDA) Clearance Of Rejoyn, The First Prescription Digital Therapeutic Authorized For The Adjunctive Treatment Of Major Depressive Disorder (MDD) Symptoms
4/1/2024
Otsuka Pharmaceutical, Co. Ltd. (Otsuka) and Click Therapeutics, Inc., (Click) announce that the U.S. Food and Drug Administration (FDA) has cleared Rejoyn (developed as CT-152), the first prescription digital therapeutic authorized for the treatment of major depressive disorder (MDD) symptoms as an adjunct to clinician-managed outpatient care for adult patients with MDD age 22 years and older who are on antidepressant medication. Rejoyn is intended to reduce MDD symptoms.
-
Synthekine Announces U.S. FDA Clearance Of IND Application For CD19 CAR-T And Orthogonal IL-2 Combination Therapy, SYNCAR-001 + STK-009, For Treatment Of Lupus Without Lymphodepletion
3/26/2024
Synthekine Inc., an engineered cytokine therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application to evaluate SYNCAR-001 + STK-009, its orthogonal IL-2 and CD19 CAR-T combination therapy, in patients with non-renal systemic lupus erythematosus (SLE) and lupus nephritis (LN), without the use of any lymphodepletion.
-
CinFina Pharma Announces FDA Clearance Of Investigational New Drug Application And First Participants Dosed In Phase 1 Trial Of CIN-110 For The Treatment Of Obesity
3/26/2024
CinFina Pharma, a CinRx portfolio company dedicated to advancing a portfolio of high-impact treatment options for obesity and metabolic diseases, today announced the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug Application (IND) for CIN-110, aPYY3-36analog, allowing the first in-human clinical study to proceed.
-
Researchers Devise New Method To Find Proteins For Targeted Treatment Of Disease
3/26/2024
Researchers at Sinai Health and the University of Toronto have created a new platform to identify proteins that can be used to control the stability of other proteins – a new and largely unrealized approach to treating diseases.
-
EPNextS Group And Frontage Laboratories, Inc. Announce Collaboration In Early Phase Clinical Trials In The United States To Improve ‘Drug Lag’ And ‘Drug Loss’ Issues In Japan
3/26/2024
EPNextS Group, a Japanese based leading provider of clinical trial solutions, and Frontage Laboratories, Inc., a US based full-service contract research organization (CRO), have announced a collaboration aimed at addressing the challenges of "Drug Lag" and "Drug Loss" in Japan.